Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rocheste...
Enregistré dans:
Auteurs principaux: | Timothy L Comstock, Paul M Karpecki, Timothy W Morris, et al |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/558707f1c679417aa2490cd37df17be9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
par: Silverstein BE, et autres
Publié: (2012) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
par: Morris TW, et autres
Publié: (2011) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
par: Haas W, et autres
Publié: (2011) -
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
par: Bucci FA Jr, et autres
Publié: (2015) -
Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
par: Gail Torkildsen, et autres
Publié: (2010)